Fidasimtamab, also known as DLTV – 1504, represents a exciting approach in the fight against multiple myeloma. The drug is a targeted antibody designed to simultaneously engage CD3-positive T cells and https://fidasimtamabliquid750610.mpeblog.com/76994516/fidasimtamab-the-promising-option-in-relapsed-refractory-myeloma-therapy